Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 10/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAT1 | P18440 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183613 | 1.00 | PTPN1 (0.50) | PTPN1HPGDAOC3PIM1PIM3 | |
| SCHEMBL6183238 | 0.92 | PTPN1 (0.48) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6183241 | 0.92 | PTPN1 (0.48) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6182139 | 0.91 | PIM1 (0.51) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6182142 | 0.91 | PIM1 (0.51) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6181931 | 0.90 | PTPN1 (0.46) | PTPN1HPGD | |
| SCHEMBL6181933 | 0.90 | PTPN1 (0.46) | PTPN1HPGD | |
| SCHEMBL6185163 | 0.89 | HSD17B2 (0.51) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6185166 | 0.89 | HSD17B2 (0.51) | PTPN1HPGDPIM1PIM3PIM2 | |
| SCHEMBL6182707 | 0.85 | PIM1 (0.49) | PTPN1HPGDPIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | PTPN1 1579/4885HPGD 492/4885AOC3 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.